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Myelodysplastic syndrome (MDS) is a family of clonal disorders character-
ized by dyshematopoiesis and susceptibility to acute myelogenous leukemia. Tumor
necrosis factor-a (TNF-a) and transforming growth factor-b (TGF-b) are cytokines
that play key roles in the pathogenesis of MDS. There have been several reports on the
presence of genetic polymorphisms in the DNA sequence encoding the leader se-
quence of the TGF-b1 protein, and in the –308 promoter region of TNF-a. The associa-
tion between TNF-a and TGF-b1 gene polymorphism and the susceptibility to MDS
and the progression of the disease was investigated. As compared with healthy control
subjects (n = 74), patients with MDS (n = 55) showed no significant deviations in ge-
notype or allele frequencies of TNF-a. Similarly, there were no differences in the dis-
tribution of TNF-a genotypes between the MDS patients with only anemia (mild
group) and those with bi- or pancytopenia (severe group). On the other hand the TT
homozygosity at codon 10 in exon 1 of TGF-b1 gene was associated with a severe de-
gree of cytopenia [95% CI OR = 4.889, p = 0.0071]. These findings suggest that the in-
vestigated genetic polymorphisms do not predispose to the development of MDS, but
that TGF-b1 gene polymorphism may affect the disease progression.
Keywords: myelodysplastic syndrome, tumor necrosis factor-alfa, transform-
ing growth factor-beta, gene polymorphism
Introduction
The myelodysplastic syndrome (MDS) comprises a distinct, albeit hetero-
geneous group of hematopoietic disorders characterized by ineffective hemato-
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poiesis and an increased propensity to marrow failure and leukemic transforma-
tion. The natural history of the disease ranges from a chronic course that may span
years to a rapid course towards leukemic progression. Clonal proliferation is a
consequence of acquired somatic mutation that confers a proliferative advantage
to cells. Clinically, patients with MDS present with variable cytopenias due to an
ineffective hematopoiesis of unknown etiology. The current classification systems
of MDS (FAB and WHO) are based on the morphological features of the bone
marrow and the blood [1, 2]. An important recent observation in this regard is the
excessive intramedullary apoptotic death seen in the bone marrow biopsies of
MDS patients, one mechanism invoked to explain the apparent discrepancy be-
tween cellular marrow and peripheral blood cytopenias [3, 4]. Abnormal cytokine
production, autoreactive T-lymphocytes and an altered interaction between the
progenitor cells and the extracellular matrix can all promote apoptosis. Several
cytokines or ligands known to have proapoptotic properties, are upregulated in
many patients with MDS. A number of studies have stressed the importance of in-
creased levels of tumor necrosis factor-a (TNF-a) in the serum and bone marrow
in promoting apoptosis [5, 6, 7]. Transforming growth factor-b (TGF-beta) is an-
other cytokine which is generally considered to be a key negative regulator of
hematopoietic stem and progenitor cells [8, 9, 10].
It has been shown that the blockade of TNF-a or Fas-ligand enhances
hematopoietic colony transformation from MDS marrow in vitro and improves
blood cell counts in vivo, thus, one of the main new directions in the treatment of
MDS is the use of compounds exerting inhibitory activity on proapoptotic cyto-
kines [11, 12, 13].
The regulatory and coding regions of cytokine genes are relatively poly-
morphic and may therefore be useful in disease association studies. It has been
demonstrated that the production of TNF-a or TGF-b1 varies from individual to
individual and partly depends on the polymorphisms of these genes. The most
widely investigated polymorphism of the TNF-a gene is the G-to-A transition in
the –308 promoter region [14]. It has been shown that an A nucleotide at position
–308 is associated with increased transcription and production of TNF-a [15, 16].
Further, several polymorphisms have been described in the TGF-b1 gene, includ-
ing a T-to-C transition at nucleotide 29, in the region encoding the signal sequence,
which results in a leucine-proline substitution at the 10th amino acid [17]. It has
been shown that TT homozygous genotypes are high TGF-b1 producers [18, 19,
20]. The correlation between the TNF-a gene polymorphism [21, 22, 23, 24, 25] or
the TGF-b1 gene polymorphism [26, 27, 28, 29] and the disease status has been
studied in a wide array of different diseases, the results suggesting that the gene
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polymorphisms of TNF-a or TGF-bmay provide a rational indicator of the disease
susceptibility or prognosis. In the present study, we have investigated whether
TNF-a gene polymorphism in the –308 promoter region or TGF-b1 gene polymor-
phism in codon 10 are associated with the development and severity of MDS.
Materials and methods
Patients
Control. A control group of 74 healthy blood donors (age, 41.31 ± 1.47, 21
to 73; 42 men and 32 women) was investigated.
Patients. Between May 2001 and January 2004, a total of 55 cases (15 men
and 40 women; age 70.69 ± 1.43, 25 to 87) with MDS documented by marrow bi-
opsy was enrolled. The diagnosis of MDS (n = 55) was based on the FAB criteria
[30] (50 of these patients had refractory anemia (RA), while 5 cases were diag-
nosed as having refractory anemia with an excess of blast (RAEB). Patients with
RAEB in transformation (RAEB-T) were considered as having acute leukemia
and were excluded. None of the patients had received specific therapeutic agents
prior to the study. They were supported only by red blood cell transfusion. Patients
were divided into two groups: mild group containing patients with only anemia
(hemoglobin<100 g/l) (n = 31), and severe group containing patients with bi- or
pancytopenia (neutrophil count <1 G/l, platelet count <100 G/l) (n = 24). Leuke-
mic transformation occurred in 6 patients; another 4 patients died due to the MDS
without leukemic transformation.
All patients and controls were of adult Hungarian ethnic origin and resided
in Hungary.
This study was performed in accordance with the ethical standards laid
down in the most recent version of the 1964 Declaration of Helsinki. The ethical
committee of the participating university had approved the study. Informed writ-
ten consent was obtained in advance from each of the patients.
DNA extraction
Genomic DNA from whole blood containing EDTA was extracted by a
standard technique (High Pure PCR Template Preparation Kit, Roche Diagnostic
Gmbh, Mannheim, Germany). The analysis of the polymorphisms was based on
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polymerase chain reaction (PCR) techniques performed in a thermal cycler
(GeneAmp PCR System 2700, Applied Biosystems, Foster City CA, USA).
TNF-a genotype assay
The G-to-A transition at position –308 in the promoter region was analyzed
by PCR-RFLP (restriction fragment length polymorphism) [14]. A single base
change at the 3’ end of primer A1 (underlined) was required for the formation of an
NcoI (Fermentas, Vilnius, Lithuania) recognition sequence CCATGG (instead of
GCATG originally found on the investigated gene)
(primer A1:5’-AGGCAATAGGTTTTGAGGGCCAT-3’ and
primer A2:5’-TCCTCCCTGCTCCGAT TCCG-3’) [14].
The reaction mixture of 100 µl contained 100 ng of genomic DNA, 20 pmol
each of the A1 and the A2 primer, 2.5 U Taq DNA polymerase, 1.5 mM MgCl2,
1 × PCR Taq polymerase buffer + (NH4)2SO4 (Fermentas, Vilnius, Lithuania) and
25 mM of each dNTP (Fermentas, Vilnius, Lithuania). The PCR conditions were
as follows: initial denaturation at 94 °C for 3 minutes; 36 cycles of 94 °C for 1 min-
ute each, 60 °C for 1 minute and 72 °C for 1 minute, and a final extension at 72 °C
for 5 minutes. The amplified product was digested with the endonuclease NcoI and
analyzed on a 12% polyacrylamide gel. The TNF G allele gives two fragments, of
87 bp and 20 bp, while the TNF A allele gives a single, 107 bp fragment.
TGF-b genotype assay
The defined single-nucleotide polymorphism T29-C in exon 1 of the
human TGF-b1 gene was determined by an amplification refractory muta-
tion system (ARMS) with a generic primer (sense),
(5’- TCCGTGGGATACTGAGACACC-3’);
and with two allele-specific antisense primers, differing from each other in only
one base at the 3’ end:
primer C: 5’-GCAGCGGTAGCAGCAGCG-3’ and
primer T: 5’- AGCAGCGGTAGCAGCAGCA-3’ [31].
The reaction mixture of 50 µl contained 100 ng of genomic DNA, 20 pmol each of
the sense and the antisense primer, 1.25 U Taq DNA polymerase, 1.5 mM MgCl2,
1 × PCR Taq polymerase buffer with (NH4)2SO4, and 25 mM of each dNTP
(Fermentas, Vilnius, Lithuania). The thermocycling procedure was as follows: ini-
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tial denaturation at 94 °C for 5 minutes; 35 cycles of 94 °C for 30 seconds each,
60 °C for 30 seconds and 72 °C for 30 seconds, and a final extension at 72 °C for
5 minutes. The PCR products were analyzed by 1.5% agarose (Sigma-Aldrich, St.
Luis, MO, USA) gel electrophoresis. The expected size of the specific amplifica-
tion product was 241 bp. Samples from 2 known homozygotic individuals and 1
heterozygotic individual, confirmed by sequencing, were included in each reac-
tion. Sequencing was performed with an automated sequencer (ABI Prism; Ap-
plied Biosystems, CA, USA).
Statistical analysis
Statistical analyses for comparison of allele and genotype frequencies be-
tween groups were made by using the c2 test, and Fisher’s exact test if one cell had
n<5. A level p<0.05 was considered statistically significant. For comparison of
age and sex between the patients and the controls, the Mann–Whitney U test and
the Fisher’s exact test was used. Statistical calculations were performed with the
GraphPad Prism4 statistical program.
The genotype frequencies for each polymorphism were tested for deviation
from the Hardy-Weinberg equilibrium by means of the c2 test, with one degree of
freedom used.
Results
The distributions of genotypes and alleles for the different polymorphisms
were consistent with those predicted by the Hardy-Weinberg equilibrium in the
patients and in the controls. The two groups were matching according to sex
(Fisher’s exact test p = 0.058), but there was a significant difference in the mean
age between the controls and the patient group (Mann-Whitney U test p<0.01).
The –308 promoter polymorphism of TNF-a
The genotypic distribution of the TNF-a gene –308 promoter G-to-A poly-
morphism is shown in Figure 1. There were no significant differences in the
TNF-a -308 promoter genotypic distribution between the patients with MDS [GG,
GA, AA = 63.6%, 30.9%, 5.5%] and the healthy controls [GG, GA, AA = 68.9%,
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28.3%, 2.8%]. Similarly, there were no differences in the distribution of TNF-a
–308 G-to-A genotypes between the MDS patients with only anemia (mild group)
[GG, GA, AA = 61.3%, 35.5%, 3.2%] and those with bi- or pancytopenia (severe
group) [GG, GA, AA = 66.6%, 25.0%, 8.4%].
The T29-C polymorphism in codon 10 of TGF-b1
Figure 2 depicts representative results relating to the TGF-b1 genotyping.
To detect the nucleotide swap, ARMS was used. By means of the two al-
lele-specific primers, the homozygote mutant (CC), the homozygote wild (TT)
and the heterozygote (TC) variants (336 bp long product) were well distinguish-
able.
The genotypic distribution of the T29-C polymorphism of the TGF-b1 gene
is shown in Figure 3. No significant difference in genotypic distribution was found
between the MDS patients overall and the healthy controls. A significant differ-
ence was observed, however, when the genotypes were taken into consideration
within the two subgroups of MDS (c2 = 10.98, p = 0.0268). To elucidate the reason
for this significance, we compared the number of TT homozygotes (high TGF-b-
producing phenotype) and C carriers (CT and CC) among the patients with mild
and severe cytopenia forms of MDS and the healthy controls (Table I), and a sig-
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Figure 1. Distribution of TNFa (–G308A) genotypes between the patients with myelodysplastic syndrome
(MDS) and the healthy controls. Chi-square test: p>0.05 comparisons between the mild group, the severe
group and the controls. Mild group: patients with only anemia; severe group: patients with bi- or
pancytopenia
nificant difference was observed (c2 = 7.75 p = 0.0207). There was also a consider-
able difference in frequency of the TT genotype between the two subgroups of
MDS (Table I). This was due to overpresentation of the TT genotype in the pa-
tients with bi- or pancytopenia (severe group) [TT = 66.7% (severe) vs. TT =
29.0% (mild)] (p = 0.0071, OR = 4.889, 95% CI 1.548 to 15.44). Alternatively, the
C carrier status (representing the CT and CC genotypes) was markedly more fre-
quent among the patients with only anemia (mild group).
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Table I
Distribution of TT homozygosity and C-carrier status of transforming growth factor (TGF-b) T29-C
(Leu10Pro) genotypes in the patients with myelodysplastic syndrome (MDS) with mild or severe cytopenia
and the healthy controls
MDS patients Healthy controls
mild cytopenia1 (n = 31) severe cytopenia2 (n = 24) (n = 74)
TGF T29-C (Leu10Pro)
genotypes
TT 29.0% (9)ab 66.7% (16)ab 44.6% (33)b
C-carrier 71.0% (22)ab 33.3% (8)ab 55.4% (41)b
a Fischer exact test: OR = 4.889, p = 0.0071; statistical analysis was performed between the TT and CT+CC
genotypes; comparison between the mild group and the severe group.
b Chi-square test: c2 = 7.75, df = 2, p = 0.0207; statistical analysis was performed between the TT and
CT+CC genotypes; comparisons between the mild group, the severe group and the controls.
1 Patients with only anemia.
2 Patients with bi- or pancytopenia.
Figure 2. PCR/ARMS analysis of the transforming growth factor (TGF-b) T29-C polymorphism. By means
of the two allele-specific primers, the homozygote mutant CC (lanes 1 and 2), the homozygote wild TT
(lanes 3 and 4) and the heterozygote TC (lanes 6 and 7) variants (336 bp long product) were well
distinguishable
Discussion
During the past few years, major progress has been made toward the under-
standing of the pathological processes of MDS. Genetic abnormalities or altered
gene expressions leading to the suppression of hematopoiesis may also be respon-
sible for the development of cytopenia. One of the genetic factors may be an aber-
ration of cytokine regulation and cytokine production, which can lead to an in-
creased apoptosis of hematopoietic progenitor cells, and aberrant hematopoiesis.
Several lines of experimental evidence show that erythropoiesis can be severely
disturbed by inflammatory mediators such as TNF-a, as TNF suppresses prolifera-
tion of erythroid progenitor cells in human marrow cultures [32, 33]. The exces-
sive production of growth inhibitory cytokines such as TNF-a in patients with
MDS has been described [5, 6, 34]. Recent data indicate that TGF-b inhibits
myeloid, erythroid, megakaryocyte and multilineage colony formation [8, 9, 10].
Accordingly, it appeared plausible to hypothetise that polymorphisms of the
TNF-a or TGF-b1 genes may be correlated with MDS or the severity of the dis-
ease.
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Figure 3. Distribution of transforming growth factor (TGF-b) T29-C (Leu10Pro) genotypes between the
patients with myelodysplastic syndrome (MDS) and the healthy controls. Chi-square test: c2 = 10.98, df = 4;
p = 0.0268 comparisons between the mild group, the severe group and the controls. Mild group:patients with
only anemia; severe group: patients with bi- or pancytopenia
In our study, however, no significant difference in –308 TNF-a polymor-
phism was observed as regards the G or A alleles when any of the forms of MDS
were compared with each other or with the controls.
TNF-a also has an apoptotic effect toward hematopoietic cells. However,
the distribution of TNF-308 gene polymorphism was similar among the patients
with a mild or a severe degree of cytopenia in MDS. Comparison of the genotype
frequencies in patients with MDS suggests that the –308 G/A polymorphism of
TNF-a does not influence the susceptibility to the disease. There are several poten-
tial reasons for failing to observe any association between the TNF-a –308 poly-
morphism and MDS. The TNF-a –308 polymorphism would appear to occur at a
transcription factor binding site in the TNF-a promoter and hence affects protein
binding, thereby altering the transcriptional activity. The transcriptional and
translational regulation and the prosttranslational protein processing are major
steps involved in the protein expression. The TNF protein expression is probably
not regulated exclusively at the transcriptional level. In complex biological sys-
tems, the effect of a single gene polymorphism in determining cytokine secretion
may be minimized through the interaction of other factors.
TGF-b isoforms are translated as prepropeptide precursors with an
N-terminal signal peptide followed by the prodomain and mature domain, and are
secreted as biologically latent forms. The Leu10Pro-(T869C) polymorphism in
exon 1 of the TGF-b1 gene is located in the signal peptide sequence that is cleaved
from the TGF-b1 precursor at the level of codon 10 [35]. This polymorphism at
codon 10, within the hydrophobic a-helix of the signal sequence, involves the re-
placement of a hydrophobic leucine residue with a small, neutral proline residue.
Such a change would alter the overall hydrophobicity of the core transport se-
quence and disrupt the a-helical structure of the region, thereby altering its ability
to direct protein transport across the endoplasmatic reticulum [17]. The T29C
polymorphism of the TGF-b1 gene does not result in a difference in the mature
TGF-b1 protein; merely the TGF-b1 protein level is reduced both in vitro and in
vivo [18, 19, 20].
On the other hand, Yokota et al. reported that the T allele of T29-C polymor-
phism was linked to a lower production of TGF-b1 [36]. The influence of the allele
at codon 10 on TGF-b production is possibly more variable, due to the cross-mod-
ulating interfaces between the signaling networks within the cells. In this study, we
have shown that in patients with MDS the TGF-b “high-producer genotype” TT
causes a 4.9-fold risk of bi- or pancytopenia as compared with the C-carriers. Pa-
tients carrying the C allele, with a concomitantly lower TGF-b1 production, have
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only anemia. As TGF-b1 is a member of the proapoptotic cytokines, it is very
likely that patients with the low-producing genotypes (CC and CT) may have a
better chance of a less severe cytopenia in MDS. Although we could not find
genotypic differences between the MDS patients overall and the healthy controls,
we observed that the genotype of the TGF-b1 gene differed significantly between
the severe and mild groups of patients. These findings indicate that the T29-C poly-
morphism of the TGF-b gene itself is not directly involved in the susceptibility to
MDS, but is rather relevant in the outcome of the disease.
Overall, the polymorphism of the TNF-a gene in the –308 promoter region
does not have a role in the regulation of the outcome of MDS. In contrast, our find-
ings of an association between the severe form of MDS and TT homozygosity sug-
gest that future studies should focus on the role of TGF-b in MDS. Following these
pilot experiments, further investigations on the polymorphisms of the TGF-b1
gene should be included in these examinations.
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